There are multiple biotech companies listed on the ASX which are one trick ponies
I do not wish to name them, but point out their market caps range from $200 million and upwards
Which brings me back to Starpharma
It is not a one trick pony
It has a technology platform that can be applied to a great many disciplines
Of course one of those is drug delivery.
It really beggars the question of why these one trick ponies have such a large market cap compared to Starpharma
Eventually the selling will dry up and we will see real value applied to our company
In the meantime we wait for the never ending submission to the FDA
New marketing and distribution agreement with a partner for our rebranded Vivagel in the Asian and European market inclusive of an upfront payment (remembering our partner in USA has indicated US$20 million) once FDA has approved NDA
Results for Viraleze trial and new marketing and distribution agreements in place
Dep Docetaxel mono and combination data from Phase 2 trials
Multiple licensing deals for our 3 Dep drugs and upfront on board fees
We may be down in the dumps at the moment
It just does not make sense the share price is so depressed with all that is going on behind the scenes
I really do wonder who is buying those institutional shares
When this baby moves it will move hard and fast
Please do your own research
The above is my opinion and should not be considered investment advice
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)